$1.6 K

ASNB Mkt cap, 02-Oct-2018

$889 K

AdvanSource Biomaterials Revenue Q3, 2019
AdvanSource Biomaterials Gross profit (Q3, 2019)630 K
AdvanSource Biomaterials Gross profit margin (Q3, 2019), %70.9%
AdvanSource Biomaterials Net income (Q3, 2019)134 K
AdvanSource Biomaterials EBIT (Q3, 2019)228 K
AdvanSource Biomaterials Cash, 31-Dec-201893 K
AdvanSource Biomaterials EV188.6 K

AdvanSource Biomaterials Revenue

AdvanSource Biomaterials revenue was $2.92 m in FY, 2018

Embed Graph

AdvanSource Biomaterials Income Statement

Annual

USDFY, 2014FY, 2015FY, 2017FY, 2018

Revenue

2.6m2.6m2.3m2.9m

Cost of goods sold

1.0m928.0k853.0k799.0k

Gross profit

1.6m1.6m1.4m2.1m

Gross profit Margin, %

62%64%63%73%

General and administrative expense

1.4m1.2m1.2m1.6m

Operating expense total

1.8m1.6m1.6m1.9m

EBIT

(207.0k)68.0k(141.0k)181.0k

EBIT margin, %

(8%)3%(6%)6%

Interest expense

359.0k386.0k368.0k383.0k

Pre tax profit

(318.0k)(509.0k)(202.0k)

Net Income

(521.0k)(318.0k)(509.0k)(202.0k)

AdvanSource Biomaterials Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

268.0k75.0k80.0k27.0k120.0k

Inventories

181.0k304.0k257.0k189.0k297.0k

Current Assets

647.0k675.0k534.0k454.0k991.0k

PP&E

2.1m2.0m1.9m1.9m1.8m

Total Assets

2.9m2.8m2.6m2.4m2.9m

Accounts Payable

231.0k295.0k276.0k450.0k544.0k

Short-term debt

50.0k50.0k150.0k145.0k

Current Liabilities

629.0k835.0k526.0k875.0k1.3m

Long-term debt

50.0k50.0k150.0k145.0k

Non-Current Liabilities

2.1m2.1m2.1m2.2m2.2m

Total Debt

100.0k100.0k300.0k290.0k

Total Liabilities

2.8m3.0m2.7m3.0m3.4m

Common Stock

21.0k21.0k21.0k21.0k21.0k

Additional Paid-in Capital

38.1m38.1m38.1m38.1m38.4m

Retained Earnings

(37.9m)(38.2m)(38.2m)(38.7m)(38.9m)

Total Equity

139.0k(168.0k)(96.0k)(601.0k)(503.0k)

Debt to Equity Ratio

-0.5 x-0.6 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

20.8 x-16.7 x-26.8 x-4 x-5.8 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

193.0k108.0k133.0k151.0k247.0k517.0k231.0k148.0k101.0k84.0k345.0k288.0k57.0k124.0k143.0k93.0k

Inventories

355.0k378.0k150.0k159.0k329.0k252.0k242.0k182.0k185.0k217.0k192.0k289.0k304.0k340.0k300.0k242.0k

Current Assets

861.0k745.0k471.0k478.0k773.0k953.0k757.0k628.0k579.0k550.0k823.0k998.0k709.0k877.0k922.0k1.0m

PP&E

2.2m2.2m2.1m2.0m2.0m2.0m1.9m1.9m1.9m1.9m1.9m1.9m1.8m1.8m1.8m1.8m

Total Assets

3.2m3.0m2.7m2.6m2.9m3.0m2.8m2.7m2.6m2.5m2.8m3.0m2.7m2.8m2.8m2.9m

Accounts Payable

262.0k142.0k147.0k247.0k327.0k217.0k186.0k305.0k309.0k336.0k364.0k366.0k474.0k562.0k535.0k535.0k

Short-term debt

100.0k100.0k50.0k50.0k50.0k50.0k150.0k150.0k145.0k145.0k145.0k145.0k140.0k

Current Liabilities

894.0k662.0k548.0k684.0k555.0k503.0k398.0k560.0k591.0k716.0k1.3m1.5m1.3m1.2m1.2m1.2m

Long-term debt

100.0k100.0k50.0k50.0k50.0k50.0k150.0k150.0k145.0k145.0k145.0k145.0k140.0k

Non-Current Liabilities

2.1m2.1m2.1m2.1m2.1m2.1m2.1m2.1m2.2m2.2m2.2m2.2m2.2m2.2m2.2m2.2m

Total Debt

200.0k200.0k100.0k100.0k100.0k100.0k300.0k300.0k145.0k290.0k290.0k290.0k280.0k

Total Liabilities

3.0m2.8m2.7m2.8m2.7m2.6m2.5m2.7m2.7m2.9m3.5m3.7m3.4m3.4m3.4m3.3m

Common Stock

21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k21.0k

Additional Paid-in Capital

38.0m38.0m38.1m38.1m38.1m38.1m38.1m38.1m38.1m38.1m38.1m38.4m38.4m38.4m38.4m38.4m

Retained Earnings

(37.8m)(37.8m)(38.0m)(38.2m)(37.9m)(37.7m)(37.8m)(38.1m)(38.3m)(38.4m)(38.8m)(39.1m)(39.2m)(39.0m)(39.0m)(38.8m)

Total Equity

206.0k251.0k10.0k(163.0k)172.0k385.0k275.0k(56.0k)(158.0k)(330.0k)(682.0k)(717.0k)(761.0k)(594.0k)(550.0k)(416.0k)

Debt to Equity Ratio

-0.2 x-0.5 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

15.6 x12.1 x268.3 x-16.2 x16.6 x7.9 x10.2 x-47.4 x-16.4 x-7.7 x-4.1 x-4.1 x-3.5 x-4.7 x-5.2 x-7 x

AdvanSource Biomaterials Cash Flow

Annual

USDFY, 2014FY, 2017FY, 2018

Net Income

(521.0k)(509.0k)(202.0k)

Depreciation and Amortization

180.0k57.0k52.0k

Accounts Payable

61.0k174.0k94.0k

Purchases of PP&E

(10.0k)

Interest Paid

235.0k349.0k373.0k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(448.0k)(407.0k)(132.0k)337.0k181.0k(111.0k)37.0k(172.0k)(81.0k)(416.0k)(91.0k)(66.0k)68.0k

Depreciation and Amortization

93.0k137.0k43.0k12.0k25.0k13.0k29.0k43.0k

Accounts Payable

92.0k(28.0k)(84.0k)247.0k298.0k327.0k217.0k186.0k305.0k336.0k(86.0k)(84.0k)18.0k(9.0k)(9.0k)

Purchases of PP&E

(10.0k)(24.0k)(24.0k)(24.0k)

Interest Paid

140.0k210.0k70.0k96.0k189.0k93.0k187.0k280.0k

AdvanSource Biomaterials Ratios

USDY, 2018

EV/EBIT

0.8 x

Financial Leverage

-7 x

AdvanSource Biomaterials Employee Rating

1.01 votes
Culture & Values
1.0
Work/Life Balance
3.0
Senior Management
1.0
Salary & Benefits
3.0
Career Opportunities
2.0
Source